Eversept Partners, LP Cure Vac N.V. Transaction History

Eversept Partners, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.94 - $4.34 $55,210 - $81,500	18,779 Added 3.78%	515,691 $1.56 Million
Q4 2023 Feb 14, 2024	SELL	$3.96 - $6.41 $78,732 - $127,443	-19,882 Reduced 3.85%	496,912 $2.09 Million
Q3 2023 Nov 14, 2023	BUY	$6.5 - $10.77 $1.04 Million - $1.72 Million	159,452 Added 44.62%	516,794 $3.53 Million
Q2 2023 Aug 14, 2023	BUY	$6.69 - $12.25 $2.39 Million - $4.38 Million	357,342 New	357,342 $3.72 Million
Q1 2022 May 16, 2022	SELL	$14.73 - $35.25 $1.25 Million - $3 Million	-85,017 Closed	0 $0
Q4 2021 Nov 08, 2023	SELL	$33.72 - $48.22 $9.18 Million - $13.1 Million	-272,325 Reduced 76.21%	85,017 $2.92 Million
Q4 2021 Feb 14, 2022	BUY	$33.72 - $48.22 $2.87 Million - $4.1 Million	85,017 New	85,017 $2.92 Million

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $538M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.